Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Oscar Ferraù is active.

Publication


Featured researches published by Oscar Ferraù.


European Journal of Clinical Investigation | 1991

HCV infection, hepatic HLA display and composition of the mononuclear cell inflammatory infiltrate in chronic alcoholic liver disease

Maria Antonietta Freni; Antonino Ajello; M. L. Resta; G. B. Gaeta; Aldo Spadaro; A. Fava; I. Calapristi; Nunziata Alessi; Oscar Ferraù

Abstract. Viral infection may play a role in alcoholic liver disease with histological features of chronic active hepatitis (CAH). Human leucocyte antigen (HLA) hepatocellular display is supposed to allow HLA‐restricted T‐lymphocyte cytotoxicity in chronic viral hepatitis.


Clinical Chemistry and Laboratory Medicine | 2005

Soluble CD30 serum levels before and after treatment with α-interferon in patients with chronic hepatitis C

Enrico Di Cesare; Aldo Spadaro; Antonino Ajello; Oscar Ferraù; Nunziata Alessi; Carmelo Luigiano; Rossana Melluso; Maria Antonietta Freni

Abstract It has been suggested that soluble CD30 (sCD30) serum levels in chronic hepatitis C are correlated with the activity of the disease and with the outcome of interferon (IFN) treatment. In this study, sCD30 serum levels in 25 patients with chronic hepatitis C, before and after treatment with IFN-2α, were measured. A total of 20 healthy subjects were used as controls. High sCD30 levels in serum were found in 36% of patients and in 5% of controls. In patients with sCD30 levels above or within the normal range, no significant differences in age, gender, serum transaminases and histology activity index were found. In relation to IFN treatment, only responder patients had serum sCD30 higher than controls, although the difference between responders and non-responders was not significant. No changes from baseline values were observed after treatment. Although high, sCD30 serum levels in chronic hepatitis C are not correlated with the disease activity, are not affected by IFN treatment and are not predictors of response to IFN treatment.


Hepatology | 1995

Focal lymphocytic aggregates in chronic hepatitis C: Occurrence, immunohistochemical characterization, and relation to markers of autoimmunity

Maria Antonietta Freni; Domenica Artuso; Guido Gerken; Cesarina Spanti; Teresa Marafioti; Nunziata Alessi; Aldo Spadaro; Antonino Ajello; Oscar Ferraù


World Journal of Gastroenterology | 2005

Serum chromogranin-A in hepatocellular carcinoma: Diagnostic utility and limits

Aldo Spadaro; Antonino Ajello; Carmela Morace; Agata Zirilli; Graziella D’arrigo; Carmelo Luigiano; Francesco Martino; Anna Bene; Domenico Migliorato; Santi Turiano; Oscar Ferraù; Maria Antonietta Freni


World Journal of Gastroenterology | 2008

High circulating D-dimers are associated with ascites and hepatocellular carcinoma in liver cirrhosis

Aldo Spadaro; Vincenza Tortorella; Carmela Morace; Agostino Fortiguerra; Paola Composto; Caterina Bonfiglio; Angela Alibrandi; Carmelo Luigiano; Giuseppe De Caro; Antonino Ajello; Oscar Ferraù; Maria Antonietta Freni


Hepato-gastroenterology | 2002

Serum thrombopoietin in chronic liver disease: Relation to severity of the disease and spleen size

Maria Antonietta Freni; Aldo Spadaro; Antonino Ajello; Elena Barbaro; Maria Scaffidi; Nunziata Alessi; Resta Ml; Oscar Ferraù


World Journal of Gastroenterology | 2006

Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma

Aldo Spadaro; Antonino Ajello; Carmelo Luigiano; Carmela Morace; Resta Ml; Grazia Berlinghieri; Salvatore Campo; Claudio Scisca; Angela Alibrandi; Graziella D’arrigo; Nunziata Alessi; Oscar Ferraù; Maria Antonietta Freni


European Journal of Internal Medicine | 2012

Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma?

Carmela Morace; M. Cucunato; R. Bellerone; G. De Caro; S. Crinò; A. Fortiguerra; Federica Spadaro; A. Zirilli; Angela Alibrandi; Pierluigi Consolo; Carmelo Luigiano; M.L. Resta; Oscar Ferraù; Aldo Spadaro


Clinical Gastroenterology and Hepatology | 2006

Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis

Luigi Bolondi; Fabio Piscaglia; Angelo Gatta; Francesco Salerno; Mauro Bernardi; Antonio Ascione; Oscar Ferraù; David Sacerdoti; Stefania Visentin; Franco Trevisani; Roberto Mazzanti; Gabriele Donati; Umberto Arena; Paolo Gentilini


Hepato-gastroenterology | 1999

Ten year follow-up of patients with chronic hepatitis C treated with interferon

Antonino Ajello; Maria Antonietta Freni; Aldo Spadaro; Nunziata Alessi; Impellizzeri F; Consolo P; Resta Ml; Oscar Ferraù

Collaboration


Dive into the Oscar Ferraù's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge